Literature DB >> 1404600

Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

M L Hammarskjöld1, M C Simurda.   

Abstract

The Epstein-Barr virus latent membrane protein (LMP) is an integral membrane protein that is expressed in cells latently infected with the virus. LMP is believed to play an important role in Epstein-Barr virus transformation and has been shown to induce expression of several cellular proteins. We performed a series of experiments that demonstrated that LMP is an efficient transactivator of expression from the human immunodeficiency virus type 1 long terminal repeat (HIV-1 LTR). Mutation or deletion of the NF-kappa B elements in the LTR abolished the transactivation, indicating that the LMP effect on HIV expression was due to induction of NF-kappa B activity. Experiments in which the HIV-1 Tat protein was coexpressed in cells together with LMP showed that Tat was able to potentiate the transactivation. Surprisingly, a synergistic effect of the two proteins was observed even in the absence of the recognized target region for Tat (TAR) in the HIV-1 LTR.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1404600      PMCID: PMC240142     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  Regulation of HIV expression: mechanisms of action of Tat and Rev.

Authors:  K T Jeang; Y Chang; B Berkhout; M L Hammarskjöld; D Rekosh
Journal:  AIDS       Date:  1991       Impact factor: 4.177

2.  Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation.

Authors:  C W Dawson; A B Rickinson; L S Young
Journal:  Nature       Date:  1990-04-19       Impact factor: 49.962

3.  HIV-associated lymphoma: histopathology and association with Epstein-Barr virus genome related to clinical, immunological and prognostic features.

Authors:  C Pedersen; J Gerstoft; J D Lundgren; P Skinhøj; J Bøttzauw; C Geisler; S J Hamilton-Dutoit; S Thorsen; I Lisse; E Ralfkiaer
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

4.  Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection.

Authors:  Y Rivière; V Blank; P Kourilsky; A Israël
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

5.  Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NF-kappa B. TNF alpha is not needed for induction of a biological effect via TNF receptors.

Authors:  H P Hohmann; M Brockhaus; P A Baeuerle; R Remy; R Kolbeck; A P van Loon
Journal:  J Biol Chem       Date:  1990-12-25       Impact factor: 5.157

6.  B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50.

Authors:  A Neri; C C Chang; L Lombardi; M Salina; P Corradini; A T Maiolo; R S Chaganti; R Dalla-Favera
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

7.  Human immunodeficiency virus induction of malignant transformation in human B lymphocytes.

Authors:  J Laurence; S M Astrin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

8.  Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma.

Authors:  M J Boyle; W A Sewell; T B Sculley; A Apolloni; J J Turner; C E Swanson; R Penny; D A Cooper
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

9.  Functionally distinct NF-kappa B binding sites in the immunoglobulin kappa and IL-2 receptor alpha chain genes.

Authors:  S L Cross; N F Halden; M J Lenardo; W J Leonard
Journal:  Science       Date:  1989-04-28       Impact factor: 47.728

10.  TAR independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes.

Authors:  D Harrich; J Garcia; R Mitsuyasu; R Gaynor
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more
  69 in total

1.  The late lytic LMP-1 protein of Epstein-Barr virus can negatively regulate LMP-1 signaling.

Authors:  K D Erickson; J M Martin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 2.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

3.  Epstein-Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen.

Authors:  Natalie Sutkowski; Gang Chen; German Calderon; Brigitte T Huber
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  Virus and cell RNAs expressed during Epstein-Barr virus replication.

Authors:  Jing Yuan; Ellen Cahir-McFarland; Bo Zhao; Elliott Kieff
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1.

Authors:  Barbara Adler; Eveline Schaadt; Bettina Kempkes; Ursula Zimber-Strobl; Barbara Baier; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

6.  Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein.

Authors:  K M Kaye; O Devergne; J N Harada; K M Izumi; R Yalamanchili; E Kieff; G Mosialos
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation.

Authors:  K M Izumi; K M Kaye; E D Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

8.  Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

Authors:  W Chen; N R Cooper
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

9.  Epstein-barr virus-induced changes in B-lymphocyte gene expression.

Authors:  Kara L Carter; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Augmented latent membrane protein 1 expression from Epstein-Barr virus episomes with minimal terminal repeats.

Authors:  Allison M Repic; Mingxia Shi; Rona S Scott; John W Sixbey
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.